Literature DB >> 23635399

The potential value of phosphohistone-h3 mitotic index determined by digital image analysis in the assessment of pancreatic endocrine tumors in fine-needle aspiration cytology specimens.

Rossitza Draganova-Tacheva1, Marluce Bibbo, Ruth Birbe, Constantine Daskalakis, Charalambos Solomides.   

Abstract

OBJECTIVE: According to the World Health Organization, pancreatic endocrine tumors are graded by assessment of the Ki67 proliferation index and/or mitotic count. The objective was to find comparable grading on the basis of the novel mitotic marker phosphohistone-H3 (PHH3). STUDY
DESIGN: A computer-assisted system was used to assess 23 cell blocks stained with PHH3 and Ki67 antibodies. We investigated possible cut-points for PHH3 and computed percent agreement between the PHH3- and Ki67-based grading.
RESULTS: The Spearman correlation between percent Ki67 positive and percent PHH3 positive was 0.76 (p = 0.001). A value of 0.3% for the lower cut-point ('cut-point 1', differentiating between grades 1 and 2) and values of about 1.8-1.9% for the higher cut-point ('cut-point 2', differentiating between grades 2 and 3) shows optimal agreement between PHH3 and Ki67 grading. The percentage of positive cells was much higher for Ki67 than for PHH3 (mean 10.6 vs. 3.0%).
CONCLUSIONS: PHH3 has good correlation with Ki67, but the range of PHH3 positivity is much narrower than that of Ki67 (range 0-4% for PHH3 vs. 0-50% for Ki67). Therefore, to be as accurate, grading on the basis of PHH3 requires evaluation of a larger number of tumor cells for a precise determination of percent PHH3-positive nuclei.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635399     DOI: 10.1159/000350885

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  7 in total

1.  Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Authors:  Eleonora Duregon; Adele Cassenti; Alessandra Pittaro; Laura Ventura; Rebecca Senetta; Roberta Rudà; Paola Cassoni
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

2.  Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma.

Authors:  Samuel A Henderson; Michael T Tetzlaff; Penvadee Pattanaprichakul; Patricia Fox; Carlos A Torres-Cabala; Roland L Bassett; Victor G Prieto; Hunter W Richards; Jonathan L Curry
Journal:  J Cutan Pathol       Date:  2014-10-28       Impact factor: 1.587

3.  Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.

Authors:  Jessica Tracht; Kui Zhang; Deniz Peker
Journal:  J Histochem Cytochem       Date:  2017-05-22       Impact factor: 2.479

4.  Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?

Authors:  Clotilde Dumars; Fanny Foubert; Yann Touchefeu; Nicolas Regenet; Hélène Senellart; Tamara Matysiak-Budnik; Marie-Françoise Heymann
Journal:  Endocrine       Date:  2016-04-05       Impact factor: 3.633

5.  Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.

Authors:  Lik Hang Lee; Hua Yang; Gilbert Bigras
Journal:  Sci Rep       Date:  2014-05-30       Impact factor: 4.379

6.  Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.

Authors:  Patricia Switten Nielsen; Rikke Riber-Hansen; Henrik Schmidt; Torben Steiniche
Journal:  Diagn Pathol       Date:  2016-04-09       Impact factor: 2.644

7.  The Utility of Phosphohistone H3 in Inter-Observer Variability of Mitotic Count in Meningioma, is There Any Benefit?

Authors:  Hana Saffar; Hoda Okhovat; Saeed Arbabsoleymani; Seyed Mohammad Tavangar; Alireza Khoshnevisan; Ghazal Hajinasrollah; Zahra Hamidi Afra; Hiva Saffar
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.